Three new low-dimensional quaternary sulfides, namely, TlCuGeS(), TlAgGeS(), and TlAgSnS() were synthesized by solid-state reactions and characterized by single-crystal X-ray diffraction, spectroscopic, thermal, and photocatalytic studies. The compounds , , and , respectively, have centrosymmetric layered, noncentrosymmetric layered, and noncentrosymmetric one-dimensional structures, in which Cu, Ge, and Sn ions have tetrahedral coordination and Ag ion has linear, trigonal planar and tetrahedral coordinations. The monovalent thallium cations have TlS dodecahedral coordination and TlS and TlS coordination polyhedra of irregular shape.
View Article and Find Full Text PDFIntroduction: Older adults with dementia who are on multiple medications are more vulnerable to the use of potentially inappropriate medications (PIMs), which can significantly increase the risk of adverse events and drug-related problems. PIMs use is prevalent and varies among older adults with dementia or cognitive impairment (CI) attending memory clinics. However, the prevalence of PIMs, polypharmacy, and hyper-polypharmacy among older adults with dementia or CI who are attending memory clinics is not well understood.
View Article and Find Full Text PDFFour new noncentrosymmetric tellurites of quaternary A/M/Te/O (A = Ba, Sr, Ca; M = V, Nb, Ta) system, namely, BaTaTeO (), BaNbTeO (), SrTaTeO (), and CaVTeO (), were synthesized and characterized by single-crystal X-ray diffraction, thermal analysis, diffuse reflectance spectroscopy, and powder second harmonic generation (SHG) response measurements. The isostructural compounds crystallize in the 222 space group and have a three-dimensional (TaTeO)/(NbTeO) anionic framework, whereas the layered compound crystallizes in the 2 space group and has a [VTeO] anionic layer. The phase-matching compounds , and and the non-phase-matching compound show powder SHG responses equivalent to ∼27, ∼13, ∼24, and ∼68% of that of LiNbO, respectively.
View Article and Find Full Text PDFBackground: Currently, only a few specific blood pressure-lowering medications are recommended for migraine prevention. Whether benefits extend to other classes or drugs is uncertain.
Methods: Embase, MEDLINE, and the Cochrane Central Registry of Controlled Trials were searched for randomized control trials on the effect of blood pressure-lowering medications compared with placebo in participants with episodic migraine.